Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00477165 · ClinicalTrials.gov registry record · Phase 2
Citalopram in Irritable Bowel Syndrome
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT00477165: Completed Phase 2 study, sponsored by Stanford University.
NCT00477165 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00477165, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
Hypotheses: 1. Primary null hypothesis: The rate of clinical response, assessed as patient-reported global symptom rating and "adequate relief of IBS symptoms," does not differ between non-depressed IBS patients treated with the SSRI citalopram and patients treated with placebo. 2. Secondary null hypotheses: 1. Changes in disease-related quality of life, assessed with the IBS-QOL instrument, do not differ between patients treated with the SSRI citalopram and patients treated with placebo. 2. Changes in rectosigmoid visceral sensitivity, assessed by barostat balloon distention, do not differ between patients treated with the SSRI citalopram and patients treated with placebo.
Interventions
- DRUG Placebo
- DRUG Citalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2001-04 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00477165
The ClinicalTrials.gov registry entry for NCT00477165 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00477165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00477165 about?
NCT00477165 is a clinical study titled "Citalopram in Irritable Bowel Syndrome". Hypotheses: 1. Primary null hypothesis: The rate of clinical response, assessed as patient-reported global symptom rating and "adequate relief of IBS symptoms," does not differ between non-depressed IBS patients treated with the SSRI citalopram and patients treated with placebo. 2. Secondary null h...
What is the current status of trial NCT00477165?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2001-04. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00477165?
The interventions under investigation include: Placebo (DRUG), Citalopram (DRUG).
Who is sponsoring clinical trial NCT00477165?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.